Opko Health PII trial of SARM and ADT

[AZjame]

From an Opko Health Jan 31 PR release:

"OPKO is planning additional exploratory Phase 2 clinical studies to assess the feasibility of OPK-88004 in other indications. One of the trials is designed to study the safety and efficacy of OPK-88004 in prostate cancer patients treated with Androgen Deprivation Therapy (ADT). ADT results in the reduction of testosterone to castration levels in men with prostate cancer. However, ADT is associated with side effects such as decreased LBM, physical function, bone quality and increases in body fat, frailty and hot flashes. The diminished quality of life results in approximately one-third of men treated with ADT stopping treatment within six months of initiation. OPKO’s trial data in aging men indicate that OPK-88004 increases LBM, decreases fat and increases physical function. Because OPK-88004 decreases PSA levels due to its antagonistic effects on the prostate, it may be well-suited to treat men on ADT therapy. The contemplated Phase 2 study is designed to show that OPK-88004 improves ADT-associated symptoms and quality of life of prostate cancer patients. Approximately one million men are receiving ADT therapy in the U.S."

I'll be closely monitoring this as many on this board may want to pursue getting in to this clinical trial.

[j-o-h-n]

OPKO Health, Inc. is a multinational pharmaceutical & diagnostics company aiming to establish leading positions in large & rapidly growing medical markets.

Good Luck, Good Health and Good Humor.

j-o-h-n Saturday 02/02/2019 1:07 AM EST